Novartis AG has reaffirmed its commitment to the gene therapy space by accessing Voyager Therapeutics, Inc's next-generation adeno-associated virus (AAV) platform in a deal that could be worth up to $1.75bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?